SLC5A2 and type 2 diabetes mellitus: However, several clinical studies performed in patients with type 2 diabetes have shown that SGLT2 inhibitors suppress the development of diabetic macroangiopathies and heart failure and also act as renal protectors [2–7], including in Asian subjects, whose body mass index (BMI) and estimated glomerular filtration rate (eGFR) are generally lower than in Western populations [8, 9].